Financial Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023 byJosh SandbergMarch 13, 2024
Biologics Regulatory Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand byJosh SandbergJanuary 31, 2024
Biologics Spine Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA byJosh SandbergDecember 27, 2023
Biologics Regulatory Spine Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications byChris StewartFebruary 3, 2022
Biologics Spine Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales byJosh SandbergOctober 26, 2021
Biologics Financial Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe byChris StewartMarch 2, 2021
Biologics Regulatory Kuros Biosciences Further Strengthens Orthobiologics Patent Portfolio byJosh SandbergJuly 23, 2020
Biologics Spine Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superiority to Market-Leading Synthetic Bone Grafts in Spinal Fusion byChris StewartJanuary 31, 2020
Biologics Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia and New Zealand byJosh SandbergJuly 9, 2019
Biologics Kuros Ends Transformational Year With First MagnetOs Sales, Lead Clinical Program on Track, and Successful Capital Raise byJosh SandbergDecember 17, 2018
